Seven Eight Capital LP Buys 11,279 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Seven Eight Capital LP boosted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 245.4% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 15,876 shares of the biotechnology company's stock after purchasing an additional 11,279 shares during the period. Seven Eight Capital LP's holdings in Ascendis Pharma A/S were worth $2,165,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Private Ocean LLC purchased a new stake in Ascendis Pharma A/S during the 1st quarter valued at about $36,000. Quadrant Capital Group LLC lifted its holdings in Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 151 shares during the period. EverSource Wealth Advisors LLC increased its position in Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after buying an additional 91 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock worth $45,000 after buying an additional 102 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new stake in Ascendis Pharma A/S during the fourth quarter valued at $126,000.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $2.57 during trading hours on Thursday, hitting $151.45. 760,448 shares of the stock were exchanged, compared to its average volume of 439,975. The company's fifty day simple moving average is $132.94 and its two-hundred day simple moving average is $136.52. The company has a market cap of $8.82 billion, a PE ratio of -15.49 and a beta of 0.63. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ASND shares. The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a research note on Tuesday. Stifel Nicolaus started coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a "buy" rating and a $200.00 target price on the stock. JPMorgan Chase & Co. dropped their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an "overweight" rating for the company in a report on Wednesday, September 4th. Bank of America raised their price objective on Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Finally, Evercore ISI increased their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a research note on Tuesday. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $193.77.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.